Triptorelin
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Triptorelin is listed as hormonal / gnrh agonist.
- •Prostate cancer
- •Central precocious puberty
- •Off-label single-dose HPTA restart
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Triptorelin; also known as Trelstar, Decapeptyl.
Pharmacologic class: Hormonal / GnRH Agonist.
Known delivery routes: Intramuscular, Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Long-acting GnRH agonist; an initial flare raises LH/FSH before receptor downregulation produces sustained suppression.
- •Reliable LH surge at microdose
- •Established depot pharmacology
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III oncology and pediatric endocrinology programs.
Laboratory Research
Phase III oncology and pediatric endocrinology programs
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Testosterone flare then suppression
- •Bone density loss with chronic use
- •Hot flashes, mood change
Contraindications
- •Pregnancy
- •Hypersensitivity to GnRH analogs
- •Osteoporosis (chronic use)
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 3.75 mg depot (oncology); 100 mcg single dose off-label
Frequency: Monthly depot, or one-time off-label
Cycling: Off-label restart use is a single microdose; repeat dosing risks axis shutdown.
Intramuscular (IM)
Used for depot formulations, some GH secretagogues (localized delivery), and clinical protocols requiring faster systemic uptake.
23–25G × 1–1.5" needle. 1–3 mL syringe. Ventrogluteal, vastus lateralis, or deltoid. Insert 90°, aspirate (optional), inject slowly. Rotate sites weekly.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Triptorelin?
In plain words
Triptorelin is a prescription drug that changes hormone signals. It first causes a brief hormone rise, then lowers hormone levels as the body becomes less responsive to its signal. It is studied and used for prostate cancer and puberty that starts too early. Long-term use can weaken bones, and other risks include hot flashes and mood changes.
Technical definition
Triptorelin (Trelstar, Decapeptyl) is a long-acting gonadotropin-releasing hormone (GnRH) receptor agonist in the hormonal drug class. Initial receptor activation raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH), producing a hormonal flare before receptor downregulation leads to sustained suppression. It is an FDA-approved prescription drug with Phase III randomized controlled trial evidence and uses in prostate cancer and central precocious puberty.
Function
Dosing
Recommended Time of Day
Any consistent time — depot injection per prescribed schedule.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Ventrogluteal — Palm on greater trochanter, index to ASIS — inject in the V. Safest IM site.
- Dorsogluteal (upper outer) — Upper outer quadrant of the buttock. Used for depot IM; alternate sides each cycle.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
- Anterior thigh (vastus lateralis) — Middle third of the outer front thigh. Preferred IM site for self-injection.
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Off-label restart use is a single microdose; repeat dosing risks axis shutdown.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Triptorelin and sync them to Vial Lab.
Benefits
- ·Reliable LH surge at microdose
- ·Established depot pharmacology
Risks
- ·Testosterone flare then suppression
- ·Bone density loss with chronic use
- ·Hot flashes, mood change
Contraindications
- ·Pregnancy
- ·Hypersensitivity to GnRH analogs
- ·Osteoporosis (chronic use)
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Triptorelin. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.